Catalyst Dossier · compiled by CeliA 🧫

Innovation Pharmaceuticals Inc. (IPIX)

Pharmaceutical Preparations · market cap $9M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Innovation Pharmaceuticals Inc. (IPIX) is a micro-cap pharmaceutical company with a market capitalization of approximately $9 million and a lead asset, F14, in Phase 3 development for post-operative pain. The company maintains an unusually broad pipeline — spanning oncology, neurology, autoimmune disease, and ophthalmology — though the mechanism of action for F14 is undisclosed and financial details including cash, runway, and revenue are unavailable. Several of the pipeline assets appear to be sponsored or partnered trials rather than wholly owned IPIX programs, which materially limits the attributable value.

The catalyst path

2026-08-15 (est.)Phase 2 · S095029imp 7/10
2026-10-15 (est.)Phase 2 · GI-101imp 7/10
2026-10-31 (est.)Phase 3 · Cenerimodimp 9/10
2026-12-25 (est.)Phase 3 · Gemcitabine hydrochloride and albumin binding paclitaxelimp 9/10
2027-02-15 (est.)Phase 2 · GI-108imp 7/10
2027-04-15 (est.)Phase 2 · S095018imp 7/10
2027-05-01 (est.)Phase 2 · S095035imp 7/10
2027-07-15 (est.)Phase 3 · Reference Drugimp 9/10

Pipeline

Asset	Phase	Indication
Standard of Care (SoC)	Phase 2	COVID-19
Kevetrin	Phase 2	Ovarian Cancer
Brilacidin	Phase 2	Head and Neck Neoplasms
F14	Phase 3	Post Operative Pain
400 mg (200 mg BID)	Phase 2	Chronic Stable Plaque Psoriasis
JI-101	Phase 2	Advanced Solid Tumors
Gemcitabine hydrochloride and albumin binding paclitaxel	Phase 3	Locally Advanced Pancreatic Cancer
SOM3355 100mg BID	Phase 2	Huntington's Chorea
ANO31905	Phase 2	Pancreatic Cancer
Tislelizumab	Phase 2	Glioblastoma Multiforme
S095018	Phase 2	Non-small Cell Lung Cancer (NSCLC)
NTI164	Phase 2	PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Cenerimod	Phase 3	Lupus Erythematosus, Systemic
GI-108	Phase 2	Advanced Solid Tumor
THR-184	Phase 2	Acute Kidney Injury
Selatogrel 8 mg	Phase 2	Acute Myocardial Infarction
temelimab 18 mg/kg	Phase 2	Multiple Sclerosis
Bupivacaine HCl	Phase 2	Total Knee Replacement
GNbAC1	Phase 2	Multiple Sclerosis
PRS-344/S095012	Phase 2	Solid Tumor

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IPIX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.